Operating Segments

6 Months Ended

Jun. 30, 2018

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended June 30,
	2018			2017
Revenues
Vaccines/BioDefense	$	1,449,044		$	990,971
BioTherapeutics		276,501			-
Total	$	1,725,545		$	990,971
Income (Loss) from Operations
Vaccines/BioDefense	$	30,299		$	197,270
BioTherapeutics		(923,960	)		(1,574,261	)
Corporate		(695,629	)		(939,838	)
Total	$	(1,589,290	)	$	(2,316,829	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	4,512		$	9,611
BioTherapeutics		5,345			8,077
Corporate		1,313			933
Total	$	11,170		$	18,621
Interest Income, Net
Corporate	$	32,948		$	5,231
Share-Based Compensation
Vaccines/BioDefense	$	12,818		$	14,973
BioTherapeutics		21,898			22,827
Corporate		55,709			56,247
Total	$	90,425		$	94,047

	Six Months Ended June 30,
	2018			2017
Revenues
Vaccines/BioDefense	$	2,258,300		$	2,321,855
BioTherapeutics		587,018			-
Total	$	2,845,318		$	2,321,855
Income (Loss) from Operations
Vaccines/BioDefense	$	(55,906	)	$	333,870
BioTherapeutics		(2,445,308	)		(2,601,816	)
Corporate		(1,482,177	)		(1,787,073	)
Total	$	(3,983,391	)	$	(4,055,019	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	8,992		$	19,380
BioTherapeutics		10,729			17,644
Corporate		2,663			2,647
Total	$	22,384		$	39,671
Interest Income, Net
Corporate	$	49,843		$	9,984
Share-Based Compensation
Vaccines/BioDefense	$	28,486		$	32,971
BioTherapeutics		50,216			72,597
Corporate		119,693			135,106
Total	$	198,395		$	240,674

	As of  June 30, 2018		As of December 31, 2017
Identifiable Assets
Vaccines/BioDefense	$	1,443,142	$	906,416
BioTherapeutics		166,364		116,344
Corporate		4,542,632		8,526,891
Total	$	6,152,139	$	9,549,651